Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.

TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“DPL”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“AGH”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and […]

Alzamend Neuro®, Inc. Announces Confidential Submission of Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock

TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend” or the “Company”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The public offering is expected to commence after the SEC completes its review process, subject to market and other conditions. This announcement does not […]

Alzamend Neuro®, Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021

Tampa. FL – (Business Newswire – November 16, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton […]

New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression

Tampa, FL, October 27, 2020 – Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer’s Association. Currently, Amyloid-β buildup in the brain is believed to be the cause of Alzheimer’s among many researchers. There have been many attempts to prevent or reverse the disease […]

Alzamend Neuro™ Announces Appointment of Dr. Eric McDade to Its Scientific Advisory Board

Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU Tampa, FL – (Business Newswire – July 16, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and […]

Alzamend Neuro™ Announces Senior Management to Participate in the 2019 Alzheimer’s Association International Conference®

Tampa, FL – (Business Newswire – July 12, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that its senior management team led by Stephan Jackman, the Company’s CEO and Ken Cragun, the Company’s CFO will be participating in the annual Alzheimer’s Association International Conference® being held in Los Angeles, CA from July […]

Alzamend Neuro™ Announces First Appointment to Scientific Advisory Board

Appoints Dr. Thomas Wisniewski, Leading Pioneer in Alzheimer’s Disease Tampa, FL – (Business Newswire – July 9, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed its first member to its Scientific Advisory Board, Dr. Thomas Wisniewski, a leading and acclaimed pioneer in the study and treatment of Alzheimer’s […]

Alzamend Neuro™ Completes New Management Team for 2019

Appoints Financial Executive, Kenneth S. Cragun, as New CFO and Treasurer Tampa, FL – (Globe Newswire – December 26, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its new Chief Financial Officer (CFO) and Treasurer. Mr. Cragun will report directly […]

Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

  Salt Lake City, UT – (Globe Newswire – November 19, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time proven industry leader to move the Company […]